ArticleInfection and drug resistance2019
Therapeutic compounds targeting Lipid II for antibacterial purposes.
Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Bacteriocins as Alternative Antimicrobial Agents for Wound-Associated Infections: Mechanisms, Activity Against Biofilms and Translational Potential.Antibiotics (Basel, Switzerland) · 2026Review
- Article
- Potential of the livestock industry environment as a reservoir for spreading antimicrobial resistance.Open veterinary journal · 2025Review
- Genomic Insights into Bacterial Antimicrobial Resistance Transmission and Mitigation Strategies.Current pharmaceutical biotechnology · 2025Review
- Antimicrobial peptides and proteins against drug-resistant pathogens.Cell surface (Amsterdam, Netherlands) · 2024Review
- Lung antimicrobial proteins and peptides: from host defense to therapeutic strategies.Physiological reviews · 2024Review
- Guarding the walls: the multifaceted roles of Bce modules in cell envelope stress sensing and antimicrobial resistance.Journal of bacteriology · 2024Review
- Histidine kinase-mediated cross-regulation of the vancomycin-resistance operon in Clostridioides difficile.Molecular microbiology · 2024Article
- Article
- Perception and protection: The role of Bce-modules in antimicrobial peptide resistance.Biochimica et biophysica acta. Biomembranes · 2024Review
- Daptomycin avoids drug resistance mediated by the BceAB transporter inMicrobiology spectrum · 2024Article
- Chemical genetic approaches for the discovery of bacterial cell wall inhibitors.RSC medicinal chemistry · 2023Review
- Architecture of a complete Bce-type antimicrobial peptide resistance module.Nature communications · 2023Article
- Biodegradable Polymers and Polymer Composites with Antibacterial Properties.International journal of molecular sciences · 2023Review
- Antibiotics and Bacterial Resistance-A Short Story of an Endless Arms Race.International journal of molecular sciences · 2023Review
- Bacterial virulence regulation through soluble peptidoglycan fragments sensing and response: knowledge gaps and therapeutic potential.FEMS microbiology reviews · 2023Article
- Milk-Derived Antimicrobial Peptides: Overview, Applications, and Future Perspectives.Probiotics and antimicrobial proteins · 2023Review
- Expanding the Landscape of Amino Acid-Rich Antimicrobial Peptides: Definition, Deployment in Nature, Implications for Peptide Design and Therapeutic Potential.International journal of molecular sciences · 2022Article
- Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.Biological reviews of the Cambridge Philosophical Society · 2022Review
- Conformational snapshots of the bacitracin sensing and resistance transporter BceAB.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance against commonly used antibiotics has emerged in all bacterial pathogens. In fact, there is no antibiotic currently in clinical use against which resistance has not been reported. In particular, rapidly increasing urbanization in developing nations are sites of major concern. Additionally, the widespread practice by physicians to prescribe antibiotics in cases of viral infections puts selective pressure on antibiotics that still remain effective and it will only be a matter of time before resistance develops on a large scale. The biosynthesis pathway of the bacterial cell wall is well studied and a validated target for the development of antibacterial agents. Cell wall biosynthesis involves two major processes; 1) the biosynthesis of cell wall teichoic acids and 2) the biosynthesis of peptidoglycan. Key molecules in these pathways, including enzymes and precursor molecules are attractive targets for the development of novel antibacterial agents. In this review, we will focus on the major class of natural antibacterial compounds that target the peptidoglycan precursor molecule Lipid II; namely the glycopeptides, including the novel generation of lipoglycopeptides. We will discuss their mechanism-of-action and clinical applications. Further, we will briefly discuss additional peptides that target Lipid II such as the lantibiotic nisin and defensins. We will highlight recent developments and future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.